Jeffrey A. Tice

Jeffrey A. Tice

Auto-generated profile, based on publicly available information

Jeffrey A. Tice

Department of Medicine, University of California San Francisco, San Francisco, California

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2008 in Annals of Internal Medicine
Verified
Journal Article
Closed access
JTJeffrey A. Tice
Jeffrey A. Tice
SCSteven R. Cummings
Steven R. Cummings
RSRebecca Smith-Bindman
Rebecca Smith-Bindman
LILaura Ichikawa
Laura Ichikawa
WBWilliam E. Barlow
William E. Barlow
KKKarla Kerlikowske
Karla Kerlikowske
Existing breast cancer prediction tools do not account for breast density, a strong risk factor for breast cancer. Tice and associates developed a breast cancer risk prediction model that incorpora... Background: Current models for assessing breast cancer risk are complex and do not include breast density, a strong risk factor for breast cancer that is routinely reported with mammography. Object...

28 June 2004 in Archives of internal medicine (1960)
Verified
Journal Article
Closed access
PDF file
MPMark J. Pletcher
Mark J. Pletcher
JTJeffrey A. Tice
Jeffrey A. Tice
MPMichael Pignone
Michael Pignone
WBWarren S. Browner
Warren S. Browner
Research from JAMA Internal Medicine — Using the Coronary Artery Calcium Score to Predict Coronary Heart Disease Events — A Systematic Review and Meta-analysis

6 September 2006 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
WBWilliam E. Barlow
William E. Barlow
EWEmily White
Emily White
RBRachel Ballard-Barbash
Rachel Ballard-Barbash
PVPamela M. Vacek
Pamela M. Vacek
LTLinda Titus-Ernstoff
Linda Titus-Ernstoff
KKKarla Kerlikowske
Karla Kerlikowske
Background: Risk prediction models for breast cancer can be improved by the addition of recently identified risk factors, including breast density and use of hormone therapy. We used prospective risk information to predict a diagnosis of breast cancer in a cohort of 1 million women undergoing screening mammography. Methods: There were 2 392 998 eligible screening mammograms from women without previously diagnosed breast cancer who had had a prior mammogram in the preceding 5 years. Within 1 year of the screening mammogram, 11 638 women were diagnosed with breast cancer. Separate logistic regression risk models were constructed for premenopausal and postmenopausal examinations by use of a stringent ( P <.0001) criterion for the inclusion of risk factors. Risk models were constructed with 75% of the data and validated with the remaining 25%. Concordance of the predicted with the observed outcomes was assessed by a concordance (c) statistic after logistic regression model fit. All statistical tests were two-sided. Results: Statistically significant risk factors for breast cancer diagnosis among premenopausal women included age, breast density, family history of breast cancer, and a prior breast procedure. For postmenopausal women, the statistically significant factors included age, breast density, race, ethnicity, family history of breast cancer, a prior breast procedure, body mass index, natural menopause, hormone therapy, and a prior false-positive mammogram. The model may identify high-risk women better than the Gail model, although predictive accuracy was only moderate. The c statistics were 0.631 (95% confidence interval [CI] = 0.618 to 0.644) for premenopausal women and 0.624 (95% CI = 0.619 to 0.630) for postmenopausal women. Conclusion: Breast density is a strong additional risk factor for breast cancer, although it is unknown whether reduction in breast density would reduce risk. Our risk model may be able to identify women at high risk for breast cancer for preventive interventions or more intensive surveillance.

1 October 2008 in The American Journal of Medicine
Verified
Journal Article
Closed access
JTJeffrey A. Tice
Jeffrey A. Tice
LKLeah Karliner
Leah Karliner
JWJudith Walsh
Judith Walsh
APAmy J. Petersen
Amy J. Petersen
MFMitchell D. Feldman
Mitchell D. Feldman

20 June 1992 in BMJ
Verified
Journal Article
Open access
PDF file
SAS. Allen
S. Allen
JTJ. Tice
J. Tice
PPP. Van de Perre
P. Van de Perre
ASA. Serufilira
A. Serufilira
EHE. Hudes
E. Hudes
SHS. Hulley
S. Hulley
OBJECTIVE--To determine whether HIV testing and counselling increased condom use and decreased heterosexual transmission of HIV in discordant couples. DESIGN--Prospective study. SETTING--Kigali, the capital of Rwanda. SUBJECTS--Cohabiting couples with discordant HIV serology results. MAIN OUTCOME MEASURES--Condom use in the couple and HIV seroconversion in the negative partners. RESULTS--60 HIV discordant couples were identified, of whom 53 were followed for an average of 2.2 years. The proportion of discordant couples using condoms increased from 4% to 57% after one year of follow up. During follow up two of the 23 HIV negative men and six of the 30 HIV negative women seroconverted (seroconversion rates of 4 and 9 per 100 person years). The rate among women was less than half that estimated for similar women in discordant couples whose partners had not been serotested. Condom use was less common among those who seroconverted (100% v 5%, p = 0.01 in men; 67% v 25%, p = 0.14 in women). CONCLUSIONS--Roughly one in seven cohabiting couples in Kigali have discordant HIV serological results. Confidential HIV serotesting with counselling caused a large increase in condom use and was associated with a lower rate of new HIV infections. HIV testing is a promising intervention for preventing the spread of HIV in African cities.

16 August 2016 in JAMA
Verified
Journal Article
Closed access
PDF file
DKDhruv S. Kazi
Dhruv S. Kazi
AMAndrew E. Moran
Andrew E. Moran
PCPamela G. Coxson
Pamela G. Coxson
JPJoanne Penko
Joanne Penko
DODaniel A. Ollendorf
Daniel A. Ollendorf
KBKirsten Bibbins-Domingo
Kirsten Bibbins-Domingo
This study estimates the cost-effectiveness of adding proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors to statin therapy for patients with heter